US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
pharma · Moderate to Severe Platysma Prominence · Chronic migraine
Merz Therapeutics
Merz Therapeutics GmbH
Merz Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
frankfurt am main, DE HQ
2020 Founded
1,312 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- frankfurt am main, DE
- Founded
- 2020
- Employees
- 1,312
- Programs
- 3
- Drugs
- 5
- Patents
- 0
Merz Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Merz Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Merz Therapeutics in public FDA and regional records.
-
clostridium botulinum, serotype e, neurotoxin (150 kda)
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in Merz Therapeutics's portfolio.
-
Development asset linked to Merz Therapeutics in public FDA and regional records.
-
Development asset linked to Merz Therapeutics in public FDA and regional records.